Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
- None.
- None.
Insights
The recent announcement regarding Silo Pharma's SPC-14 efficacy in preclinical studies is significant for the Alzheimer's treatment landscape. Alzheimer's disease is a chronic neurodegenerative condition that currently has limited treatment options and any potential therapeutic that shows promise in preclinical stages is of immense interest to the medical community. The reported effectiveness of SPC-14 in reducing symptoms related to stress and anxiety in animal models indicates potential for addressing behavioral symptoms associated with Alzheimer's, which can be as debilitating as cognitive decline.
From a research perspective, the use of luteinizing hormone (LH) stress models is noteworthy, as LH has been implicated in the pathology of Alzheimer's disease. The attenuation of learned helplessness and perseverative behavior in mice suggests that SPC-14 may have an impact on the psychological aspects of neurodegenerative diseases, a domain often overlooked in Alzheimer's research. The mention of past studies in female rodents also highlights a gender-specific approach, which is crucial given the higher prevalence of Alzheimer's in women.
For investors, Silo Pharma's announcement could signal an inflection point in the company's valuation and future prospects. The transition from preclinical to clinical studies often acts as a catalyst for biopharmaceutical stocks. While the news is promising, investors should consider the inherent risks associated with drug development, particularly in the notoriously challenging field of Alzheimer's therapeutics. The market for Alzheimer's treatments is substantial, with the global Alzheimer's drugs market size valued at several billion dollars and growing due to an aging population.
It's important to note that the road from preclinical success to marketable drug is fraught with high attrition rates. Should SPC-14 progress to clinical trials and demonstrate safety and efficacy in humans, it could position Silo Pharma advantageously in a competitive market. However, until such results are obtained and regulatory approvals granted, the investment remains speculative.
The implications of Silo Pharma's SPC-14 on the broader market extend beyond the direct impact on Alzheimer's disease treatments. The company's approach, leveraging traditional therapeutics and psychedelic treatments, could disrupt the current market by introducing novel mechanisms of action against neurodegenerative diseases. The successful development of SPC-14 could encourage other market players to invest in similar research, potentially leading to a surge in innovation within this sector.
Moreover, the focus on behavioral symptoms such as helplessness and anxiety is reflective of a growing trend in the pharmaceutical industry to address comprehensive patient well-being. If SPC-14 proves effective in humans, it may set a precedent for future drug development that aims for a holistic treatment approach, potentially influencing patient care standards and healthcare provider strategies.
Preclinical study shows SPC-14’s effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety.
SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals.
Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic.
“We believe that today's announcement, along with our past studies of SPC-14 conducted in female rodents, lends credibility to our discovery of a therapeutic that could bring relief to patients and families suffering from Alzheimer’s disease, a debilitating disease that degrades cognitive function and can erase a lifetime of memories. We look forward to updating our shareholders on the next steps and data needed to advance SPC-14 to a clinical study,” stated Eric Weisblum, Chief Executive Officer of Silo Pharma.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the ticker symbol for Silo Pharma, Inc.?
What were the positive results announced by Silo Pharma, Inc.?
What did the preclinical study demonstrate about SPC-14?
Who is the Chief Executive Officer of Silo Pharma, Inc.?
What is the next step for SPC-14 according to Silo Pharma, Inc.?
